| P/E (FY) | — | Sales (TTM) | $0 |
| Earnings (TTM) | -$221.0M | ROE | −44.02% |
| Net Margin | — | ROIC | −171.84% |
| Debt / Equity | — | TD / EBITDA | — |
| EPS Growth 3Y | — | Sales Growth 3Y | — |
Cullinan Therapeutics is a clinical-stage biopharmaceutical company developing therapies for autoimmune diseases and cancer in the United States. Its candidates include the CLN-978 CD19xCD3 bispecific T cell engager, Velinotamig, and CLN-049 for autoimmune diseases and leukemia, plus Zipalertinib, an oral EGFR inhibitor in a Phase 2b trial for EGFR ex20ins non-small cell lung cancer. It holds a license agreement with Chongqing Genrix Biopharmaceutical.
| Market Cap | $1.07B | Trading Days | 3023 |
| 52W High | 19.43 |
| 52W Low | 5.68 |
| % Off High | −10.09% |
| YTD | 68.79% | 1Y | 112.27% |
| 3Y | 71.27% | 5Y | −31.52% |
| 10Y | 24857.14% | Since incept. (ann.) | 25.11% |
| Ann. Volatility (1Y) | 80.45% | Ann. Volatility (3Y) | 69.24% |
| Sharpe (1Y) | 1.33 | Sharpe (3Y) | 0.61 |
| Max Drawdown (1Y) | −31.06% | Max Drawdown (3Y) | −80.41% |
| Beta (3Y, vs SPY) | −0.57 |
| Ticker | Name | Mkt cap | P/E |
|---|---|---|---|
| VOR | Vor Biopharma Inc. | $1.08B | — |
| MGTX | MeiraGTx Holdings plc | $1.09B | — |
| INBX | Inhibrx Biosciences, Inc. | $1.17B | — |
| NVAX | NOVAVAX INC | $1.21B | 2.9 |
| SANA | Sana Biotechnology, Inc. | $915.6M | — |
| ODTX | Odyssey Therapeutics, Inc. | $914.0M | — |
| RXRX | RECURSION PHARMACEUTICALS, INC. | $1.36B | — |
| SLDB | Solid Biosciences Inc. | $784.6M | — |
| VIR | Vir Biotechnology, Inc. | $1.49B | — |
| MAZE | Maze Therapeutics, Inc. | $1.54B | — |
| TSHA | Taysha Gene Therapies, Inc. | $1.57B |
| — |
| AURA | Aura Biosciences, Inc. | $728.9M | — |
